CA2030133A1 - Pyridazine derivatives, process for their preparation and pharmaceutical compositions containing them - Google Patents
Pyridazine derivatives, process for their preparation and pharmaceutical compositions containing themInfo
- Publication number
- CA2030133A1 CA2030133A1 CA002030133A CA2030133A CA2030133A1 CA 2030133 A1 CA2030133 A1 CA 2030133A1 CA 002030133 A CA002030133 A CA 002030133A CA 2030133 A CA2030133 A CA 2030133A CA 2030133 A1 CA2030133 A1 CA 2030133A1
- Authority
- CA
- Canada
- Prior art keywords
- methyl
- phenyl
- substituted
- group
- propyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims description 15
- 238000002360 preparation method Methods 0.000 title claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 6
- 150000004892 pyridazines Chemical class 0.000 title abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 35
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 31
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 29
- 239000000460 chlorine Substances 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract description 12
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 8
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 8
- 239000011707 mineral Substances 0.000 claims abstract description 8
- 239000001257 hydrogen Substances 0.000 claims abstract description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 7
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims abstract description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 5
- 150000007522 mineralic acids Chemical class 0.000 claims abstract description 5
- 150000007524 organic acids Chemical class 0.000 claims abstract description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 4
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims abstract description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 4
- 235000005985 organic acids Nutrition 0.000 claims abstract description 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims abstract description 3
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims abstract description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 3
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 3
- 150000002367 halogens Chemical class 0.000 claims abstract description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 3
- 125000004076 pyridyl group Chemical group 0.000 claims abstract description 3
- 125000001544 thienyl group Chemical group 0.000 claims abstract description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims abstract 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract 4
- 150000002431 hydrogen Chemical class 0.000 claims abstract 2
- 239000004480 active ingredient Substances 0.000 claims description 10
- 150000001412 amines Chemical class 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 5
- IBWYHNOFSKJKKY-UHFFFAOYSA-N 3-chloropyridazine Chemical compound ClC1=CC=CN=N1 IBWYHNOFSKJKKY-UHFFFAOYSA-N 0.000 claims description 4
- UPNNBTDQWUFTGV-UHFFFAOYSA-N 2-n,2-n-diethyl-2-methyl-1-n-(6-phenyl-5-propylpyridazin-3-yl)propane-1,2-diamine Chemical compound CCCC1=CC(NCC(C)(C)N(CC)CC)=NN=C1C1=CC=CC=C1 UPNNBTDQWUFTGV-UHFFFAOYSA-N 0.000 claims description 2
- SFUQGDZOLMVMOP-UHFFFAOYSA-N 1-n-(5,6-diphenylpyridazin-3-yl)-2-n,2-n-diethyl-2-methylpropane-1,2-diamine Chemical compound C=1C=CC=CC=1C=1N=NC(NCC(C)(C)N(CC)CC)=CC=1C1=CC=CC=C1 SFUQGDZOLMVMOP-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 108010009685 Cholinergic Receptors Proteins 0.000 abstract description 3
- 102000034337 acetylcholine receptors Human genes 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 description 29
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 14
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- -1 hetero-cyclic radical Chemical class 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 4
- 229910052753 mercury Inorganic materials 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 description 4
- 229960004633 pirenzepine Drugs 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- OKQNWAJBDNOPAI-UHFFFAOYSA-N 2-n,2-n-diethyl-2-methylpropane-1,2-diamine Chemical compound CCN(CC)C(C)(C)CN OKQNWAJBDNOPAI-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000000044 Amnesia Diseases 0.000 description 3
- 208000031091 Amnestic disease Diseases 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 150000001336 alkenes Chemical class 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 230000006986 amnesia Effects 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- VPCDQGACGWYTMC-UHFFFAOYSA-N nitrosyl chloride Chemical compound ClN=O VPCDQGACGWYTMC-UHFFFAOYSA-N 0.000 description 3
- 235000019392 nitrosyl chloride Nutrition 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- KDSNLYIMUZNERS-UHFFFAOYSA-N 2-methylpropanamine Chemical compound CC(C)CN KDSNLYIMUZNERS-UHFFFAOYSA-N 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 2
- 239000004157 Nitrosyl chloride Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 2
- 229960002646 scopolamine Drugs 0.000 description 2
- 108010080511 serum sodium transport inhibitor Proteins 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000010183 spectrum analysis Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- AEOGOPZZLSQJKM-VQYXCCSOSA-N (e)-but-2-enedioic acid;2-n,2-n-diethyl-2-methyl-1-n-(6-phenyl-5-propylpyridazin-3-yl)propane-1,2-diamine Chemical compound OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.CCCC1=CC(NCC(C)(C)N(CC)CC)=NN=C1C1=CC=CC=C1.CCCC1=CC(NCC(C)(C)N(CC)CC)=NN=C1C1=CC=CC=C1 AEOGOPZZLSQJKM-VQYXCCSOSA-N 0.000 description 1
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical compound OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 description 1
- BVKRBMWWTJMEHE-UHFFFAOYSA-N 2-(diethylamino)-2-methylpropanenitrile Chemical compound CCN(CC)C(C)(C)C#N BVKRBMWWTJMEHE-UHFFFAOYSA-N 0.000 description 1
- GSFNQBFZFXUTBN-UHFFFAOYSA-N 2-chlorothiophene Chemical compound ClC1=CC=CS1 GSFNQBFZFXUTBN-UHFFFAOYSA-N 0.000 description 1
- ASJSAXJWTURERC-UHFFFAOYSA-N 2-n,2-n-diethyl-1-n-[6-(2-methoxyphenyl)-5-methylpyridazin-3-yl]-2-methylpropane-1,2-diamine Chemical compound N1=NC(NCC(C)(C)N(CC)CC)=CC(C)=C1C1=CC=CC=C1OC ASJSAXJWTURERC-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- CEOUJEVCFBHBJY-UHFFFAOYSA-N 4-propylpyridazine Chemical compound CCCC1=CC=NN=C1 CEOUJEVCFBHBJY-UHFFFAOYSA-N 0.000 description 1
- AIWPLDFHLYZOHF-UHFFFAOYSA-N 6-chloro-3-phenyl-4-propylpyridazine Chemical compound CCCC1=CC(Cl)=NN=C1C1=CC=CC=C1 AIWPLDFHLYZOHF-UHFFFAOYSA-N 0.000 description 1
- USVZHTBPMMSRHY-UHFFFAOYSA-N 8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]-9-[2-(2-chlorophenyl)ethyl]purin-6-amine Chemical compound C=1C=2OCOC=2C=C(Br)C=1SC1=NC=2C(N)=NC=NC=2N1CCC1=CC=CC=C1Cl USVZHTBPMMSRHY-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- MESVYYLKRQUERR-VQYXCCSOSA-N C(\C=C\C(=O)O)(=O)O.C(C)N(C(CNC=1N=NC(=C(C1)CCC)C1=C(C=CC=C1)Cl)(C)C)CC.C(\C=C\C(=O)O)(=O)O.C(\C=C\C(=O)O)(=O)O.C(C)N(CC)C(CNC=1N=NC(=C(C1)CCC)C1=C(C=CC=C1)Cl)(C)C Chemical compound C(\C=C\C(=O)O)(=O)O.C(C)N(C(CNC=1N=NC(=C(C1)CCC)C1=C(C=CC=C1)Cl)(C)C)CC.C(\C=C\C(=O)O)(=O)O.C(\C=C\C(=O)O)(=O)O.C(C)N(CC)C(CNC=1N=NC(=C(C1)CCC)C1=C(C=CC=C1)Cl)(C)C MESVYYLKRQUERR-VQYXCCSOSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 101100353161 Drosophila melanogaster prel gene Proteins 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 229910017852 NH2NH2 Inorganic materials 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000091 aluminium hydride Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- WFKAJVHLWXSISD-UHFFFAOYSA-N anhydrous dimethyl-acetamide Natural products CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 1
- 229910010277 boron hydride Inorganic materials 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- HEWVAQVRDUUHIV-UHFFFAOYSA-N chembl169829 Chemical compound N1=NC(NCC(C)(C)N(CC)CC)=CC(C)=C1C1=CC=CC=C1O HEWVAQVRDUUHIV-UHFFFAOYSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- RCJVRSBWZCNNQT-UHFFFAOYSA-N dichloridooxygen Chemical compound ClOCl RCJVRSBWZCNNQT-UHFFFAOYSA-N 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- VLPPEXVQPVETIM-UHFFFAOYSA-N ethyl 3-benzoyl-2-hydroxyhexanoate Chemical compound CCOC(=O)C(O)C(CCC)C(=O)C1=CC=CC=C1 VLPPEXVQPVETIM-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- QXUAFCKBYYPTPQ-ZWKAXHIPSA-L magnesium (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol octadecanoate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O QXUAFCKBYYPTPQ-ZWKAXHIPSA-L 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- BAQLUVXNKOTTHU-UHFFFAOYSA-N metofenazate Chemical compound COC1=C(OC)C(OC)=CC(C(=O)OCCN2CCN(CCCN3C4=CC(Cl)=CC=C4SC4=CC=CC=C43)CC2)=C1 BAQLUVXNKOTTHU-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000011302 passive avoidance test Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- TVPRCLHSULCNLV-UHFFFAOYSA-N pyridazin-3-one Chemical compound O=C1C=CC=N[N]1 TVPRCLHSULCNLV-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- RBWSWDPRDBEWCR-RKJRWTFHSA-N sodium;(2r)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethanolate Chemical compound [Na+].[O-]C[C@@H](O)[C@H]1OC(=O)C(O)=C1O RBWSWDPRDBEWCR-RKJRWTFHSA-N 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- XKGLSKVNOSHTAD-UHFFFAOYSA-N valerophenone Chemical compound CCCCC(=O)C1=CC=CC=C1 XKGLSKVNOSHTAD-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
ABSTRACT OF THE DISCLOSURE
The invention relates to pyridazine derivatives of formula :
(I) in which :
-Ar represents a phenyl group substituted by R1 and R2 or a heterocyclic radical such as a pyridyl group, unsubstituted or substituted by methyl or methoxy, or a thienyl group, unsubstituted or substituted by chlorine, methyl or methoxy ;
-R1 and R2 each independently denotes hydrogen, halogen, trifluoromethyl, hydroxyl, C1-C4 alkoxy or C1-C4 alkyl ;
-R3 represents linear or branched C1-C4 alkyl, C3-C7 cycloalkyl, benzyl, phenethyl or the Ar' radical, Ar' being phenyl substituted by R1 and R2 ;
-R4 represents :
a group, with n = 0 or 1 in which X1 represents hydrogen or methyl ;
-R5 represents a C1-C6 linear alkyl group ;
-R6 represents a C1-C6 linear alkyl group, or R5 and R6 also constitute with the nitrogen atom to which they are attached a heterocycle selected from morpholine, pyrrolidine or piperidine ;
as well as its salts with mineral or organic acids.
The above compounds are useful as drugs, notably as drugs active on the cholinergic receptors of type M1.
The invention relates to pyridazine derivatives of formula :
(I) in which :
-Ar represents a phenyl group substituted by R1 and R2 or a heterocyclic radical such as a pyridyl group, unsubstituted or substituted by methyl or methoxy, or a thienyl group, unsubstituted or substituted by chlorine, methyl or methoxy ;
-R1 and R2 each independently denotes hydrogen, halogen, trifluoromethyl, hydroxyl, C1-C4 alkoxy or C1-C4 alkyl ;
-R3 represents linear or branched C1-C4 alkyl, C3-C7 cycloalkyl, benzyl, phenethyl or the Ar' radical, Ar' being phenyl substituted by R1 and R2 ;
-R4 represents :
a group, with n = 0 or 1 in which X1 represents hydrogen or methyl ;
-R5 represents a C1-C6 linear alkyl group ;
-R6 represents a C1-C6 linear alkyl group, or R5 and R6 also constitute with the nitrogen atom to which they are attached a heterocycle selected from morpholine, pyrrolidine or piperidine ;
as well as its salts with mineral or organic acids.
The above compounds are useful as drugs, notably as drugs active on the cholinergic receptors of type M1.
Description
203~ 3~
P~RIDAZINE DERIVATIVES, PROCESS FOR_THEIB PREPARATION
A~D PHARMACEUTICAL COMPOSITIONS CONTAINING T~EM
~or many years pyridazine derivatives have been sug~ested as ~edicines, in particular medicines active on the cardiovascular system or on the central nervous system.
In particular, French patent 2 510 99~ and European patent 72 726 disclose pyridazine derivatives variously substituted on the pyridazine ring and all bearing at position 3 an amine substituent of the type ~ -alkylene-,`~l in which X and Y independently represent hydrogen, alkyl or form together with the nitrogen atom to which they are attached a heterocycle such as morpholine.
.~11 of these co~pounds exilibit an activity on the central nervous system as antidepressants.
-~ccording to the present invention, novel derivatives o~
pyridazine have now been discovered which have lost their antidepressant activity and acquired a useful activity as li~ands of cholinergic receptors, in particular receptors of the Ml type.
In accordance with a first feature, the object of the prescnt invention is novel derivatives of pyridazine corresponding to the formula:
Ar ~ ~ NH-~4 (I) in which - Ar represents a phenyl group substituted by Rl and R2 or a hetero-cyclic radical such as a pyridyl group, unsubstituted or substituted by methyl or methoxy, or a thienyl group, unsubstituted or substituted by chlorine, methyl or methoxy;
~ Rl and ~2 each independently denotes hydrogen, halogen, trifluoro-methyl, hydroxy, C1-C4 alkoxy or Cl-C4 alkyl;
- R3 represents a C1-C4 linear or branched allcyl, C3-C7 cycloalkyl, benzyl, phenethyl or the ~r' radical, I~r' being phenyl substituted by P~l and g2;
..
.- . - - . - :
- . . :.
.. ,, . . , ~ .
:,.. - ~ , : . . . . :
': . . - ~
203~3~
- R4 re?resents:
Cl~2Xl R5 a ~ CH2 - C - (Cl~2)n ~ N \ group9 with n = 0 or 1 CH2X1 ~6 in ~/hich ~1 represents hydrogen or methyl;
- R5 represents a Cl-C6 linear alkyl group;
- !?~ represents a Cl-C, linear al'.cyl group, or R5 and R6 also constitute together with the nitrogell atom to which they are attached a hetero-cycle selected from morpholine, pyrroli(line or piperidine;
as well as their salts with organic or mineral acids.
Preferentially, .~r represents phenyl, unsubstituted or mono-substituted at position 2, more particularly ~r represents a group selected from phenyl, 2-'nalo~phenyl, in particular 2-chloro-pll~llyl, 2-metho~y-phenyl or 2-hydro~y-phenyl, ?~3 represents phenyl or n-propyl, T-5 and R~ each represents ethyl, n = 0 and ~1 = H.
The followin~ co;npounds ~re particularly preferred:
P~RIDAZINE DERIVATIVES, PROCESS FOR_THEIB PREPARATION
A~D PHARMACEUTICAL COMPOSITIONS CONTAINING T~EM
~or many years pyridazine derivatives have been sug~ested as ~edicines, in particular medicines active on the cardiovascular system or on the central nervous system.
In particular, French patent 2 510 99~ and European patent 72 726 disclose pyridazine derivatives variously substituted on the pyridazine ring and all bearing at position 3 an amine substituent of the type ~ -alkylene-,`~l in which X and Y independently represent hydrogen, alkyl or form together with the nitrogen atom to which they are attached a heterocycle such as morpholine.
.~11 of these co~pounds exilibit an activity on the central nervous system as antidepressants.
-~ccording to the present invention, novel derivatives o~
pyridazine have now been discovered which have lost their antidepressant activity and acquired a useful activity as li~ands of cholinergic receptors, in particular receptors of the Ml type.
In accordance with a first feature, the object of the prescnt invention is novel derivatives of pyridazine corresponding to the formula:
Ar ~ ~ NH-~4 (I) in which - Ar represents a phenyl group substituted by Rl and R2 or a hetero-cyclic radical such as a pyridyl group, unsubstituted or substituted by methyl or methoxy, or a thienyl group, unsubstituted or substituted by chlorine, methyl or methoxy;
~ Rl and ~2 each independently denotes hydrogen, halogen, trifluoro-methyl, hydroxy, C1-C4 alkoxy or Cl-C4 alkyl;
- R3 represents a C1-C4 linear or branched allcyl, C3-C7 cycloalkyl, benzyl, phenethyl or the ~r' radical, I~r' being phenyl substituted by P~l and g2;
..
.- . - - . - :
- . . :.
.. ,, . . , ~ .
:,.. - ~ , : . . . . :
': . . - ~
203~3~
- R4 re?resents:
Cl~2Xl R5 a ~ CH2 - C - (Cl~2)n ~ N \ group9 with n = 0 or 1 CH2X1 ~6 in ~/hich ~1 represents hydrogen or methyl;
- R5 represents a Cl-C6 linear alkyl group;
- !?~ represents a Cl-C, linear al'.cyl group, or R5 and R6 also constitute together with the nitrogell atom to which they are attached a hetero-cycle selected from morpholine, pyrroli(line or piperidine;
as well as their salts with organic or mineral acids.
Preferentially, .~r represents phenyl, unsubstituted or mono-substituted at position 2, more particularly ~r represents a group selected from phenyl, 2-'nalo~phenyl, in particular 2-chloro-pll~llyl, 2-metho~y-phenyl or 2-hydro~y-phenyl, ?~3 represents phenyl or n-propyl, T-5 and R~ each represents ethyl, n = 0 and ~1 = H.
The followin~ co;npounds ~re particularly preferred:
3-(2-diethylamino-2-methyl-propyl)amino-6-phenyl-5-propyl-pyridazine and its salts;
3-(2-cliethylamino-2-methyl-propyl)amino-5,6-diphenyl-pyridazine and its salts.
The salts of the compounds of formula I accorcling to the present inventiotl includes those with both mineral and organic acids which enable the compounds of formula I to be separated or suitably crystallized, such as picric acid or oxalic acid, those which form pharmaceutically acceptable salts such as the hydrochloride, hydrobromide, sulfate, hydrogen sulfate, dihydrogen phosphate, methane sulfonate, methyl sulfate, maleate, fumarate, 2-napht~alene sulfonate.
In accordance with a second feature, the present invention relates to a process for the preparation of the compounds of formula (I).
.~ccording to the present invention, the process for the preparation of the compounds of Eormula (I) is characterized in that an amine ~4N7~2 is reacted with a 6-chloro pyridazine of formula:
: ' :
203~33 Ar--<~Cl (II) N_N
in which Ar and R3 have the meanin2s indicated above Eor (I) and, optionally, the compound thus obtained is converted into a salt with a mineral or orOanic acid.
The substitution reaction of the 6-chloro pyrida2ine (II) by the amille R4~H2 is carried out between 100 and 150C, optionally in the presence of ammonium chloride. The reaction is performed without solvent or in the presence of an inert solvent such as n-butanol. ~le product (I) is isolated by extraction and purified, for example, by chromato~raphy.
The product oE formula I thus obtained is isolated in the form of the free base or a salt according to standard techniques.
'lhen the compound of formula I is obtained in the Eorm of the free base, salt formation is carried out by treatment with the selected acid in an organic solvent. By treatment of the free base, dissolved for example in an alcohol such as isopropanol, with a solution oE the selected acid in the same solvent, the correspondin~ salt is obtained which is isolated according to standard techniques. In this way, the hydrochloride, the hydrobromide, the sulfate, the hydrogen sulfate, the dihydrogen phosphate, the methane sulfonate, the methyl sulfate, the oxalate, the maleate, the Eumarate and the 2-naphthalene sulfonate are prepared.
At the end o-E the reaction, the compound of formula I may be isolated in the form of one of its salts, for example the hydrochloride; in this case, if necessary, the free base may be prepared by neutraliæation of the said salt with a mineral or organic base such as sodium hydroxide or triethylamine or an alkali metal carbonate or bicarbonate such as sodium or potassium carbonate or bicarbonate.
~lhen Rl andjor R2 represent a hydroxyl group, the compound according to the invention is obtained startino from compound ~I) in which Rl and/or R2 denote alkoxy and all of the other substituents :
, . . , ~ - - -- . - - : :: ~
~ : ' i - : ~: :
203~3~
have the above definitions, I)y deallcylation using 1cno~/n methods.
The 6-chloro pyridazines (II), used as startino materials, are prepared from the correspon(ling 211-pyrldazin-3-ones (III) by reaction ~ith an e~cess of hot phosphorus oxychloride in the absence oE a solvent or in the presence of an inert solvent such as acetonitrile, accordino to the :Eollot~ing reaction scheme:
Ar ~\ ~ O POCl3 ~II) N-N -->
H
(III) 15The 2EI-pyridazin-3-ones ~III) are known or prepared by known methods.
Tl1us, when P~3 is a Ar' radical, the 211-pyridazin-3-ones are obtainetl according to the method described by P.SCf{MIDT et al. in llelv .
Chim. Acta, l954, 15, 134-140, starting Erom malonic acid tliethyl ester 20antl a hydrazone derivative according to the follo~ino reaction scheme:
Ar'-CO-C-Ar + CH2-CO2C2H5 25Ar~ C02C2Hs Ar~ COOH
- > Ar ~ O - > Ar ~ O
N-N N-H H
Ar' :
- > Ar ~ ~ O :
-N :
1 ~: :
(III) ~ -. .- . ~
2~3~3~
11hen ~3 represents an alkyl or cycloallcyl radical, the compoun(1s ~III) are prepared ~rom a ketone Ar-CO-C~2R3 (1):
CllO R3 OH
COOC2Hs CH-CH
5 Ar-C-C112-R3 -> Ar - C C = O
l 1~sC20 2 lO NH2NH2 CH-CH\ C=C
-----> Ar - C C = O > Ar - C\\ C = O ~
N - N N - ~ -3 ~ (III) H
The hydro~y keto ester 2 is obtained from the ketone 1 by heating it with ethyl ~lyoxylate at a temperature between 80 and 140C.
The crude reaction mixture is then taken up in an inert solvent such as n-butanol and hydrazine hydrate is added. By heating at refluc for 24 hours, the 4,5-dihydro 4-hydro~y pyridazin-3-one 3 is obtained which, when heated in an acidic medium, leads by dehydration to the 211-pyridazin-3-one (III).
The amines R4N112 are known or prepared by lcnown methods.
Thus, when n = O, they rnay be prepared from a cyano derivative of formula:
XlCHz OH
C (IV) XlCH2 CN
By reaction with an amine H~R5R6 by heating at a temperature between 40 and 80C, optionally in the presence of a salt of a strong acid such as sodium sulfate or magnesium sulfate, a compound of formula:
X lCH2 NR5R6 C ~V) XlCH2 CN
:
--. :
, . . - ~ . . ~ .
2~3~3~
is first prepared, then this compound is hydrated by reaction with a strong acid such as hot sulEuric acid in order to produce the corresponding aMide:
XlCH2 / NR5R6 C \ (VI) XlCH2 CONH2 Finally, reduction by heating with a metal hydride such as boron hydride or lithium aluminium hydride leads to the formation of the amine R4Nll2.
~ lhen n = O, the amine P~4N!12 may also be prepared from a chloronitroso derivative (VII) accordino to the procedure described in J. Prakt. Chem., 1978, 320 (3), 433-451.
Xl,CH2 XlCH2 C1 - C - CH2NO + R5R6NH2 - ~ R6RsN - C - CH = NOH
XlCH2 XlCH2 : `
(VII) (VIII) Li Al H4 XlCH2 > R6R5N - C - CH2 - NH2 X lCH2 The compound of formula (VII) may be used in the form o:E
a dimer (VIIa) which is obtained by reaction of nitrosyl chloride with the appropriate olefin (IX) according to the procedure described in J. Prakt. ChemO, 1965, 29 (4), 123.
,C,112 C1~l2Xl ~ O C~2~1 C + NOCl > Cl - C - CH2 - N = N - CH2 - C - Cl X lCH2 CH2X 1 CH2X 1 C112X 1 (IX) (VII a ) ~: . . . -2~3~33 Finally, when n = 1, the amine R4NH2 may be prepared according to the mcthod described in ~eilstein 4 (3)I 5~6, i.e. by reaction o lithiuln aluminium hydride on the oxime (X):
CII2X1 LiAlH4 CI12Xl IIo - N = CH - C - C~Iz - NR5a6 > H2N - CH2 - C - CH2- NRsR6 (X) ine ~II2 ~ CX2C(CI3)2 ~ CH2-~(C~I3)2 is commercially available.
The following exaIllples illustrate the invention without in any way limiting it. The compounds are characterized by their melting point (~I.p.) expressed in degrees centigrade.
E~A,IPLE 1 3-(2-diethylamino-2-methyl-propyl)amino-6-phenyl-5-propyl-pyridazine sesquifumarate: SR 46559 ,~.
A~ 6-chloro-3-phenyL-4-propyl-pyridazine.
1. Ethyl 2-hydroxy-4-oxo-4-phenyl-3-propyl-butyrate.
A mixture of 48.c,7 g of valerophenone and 45.94 g of ethyl ~lyoxylate is heated at 120C Eor 15 hours.
The crucle reaction product is used as such in the following step, 2. 6-phenyl-5-propyl-2rl-pyridazin-3-one.
The crude product obtained above is dissolved in 450 ml of n-butanol, then 30 g of hydrazine hydrate are added and the mixture is heated at reflux -Eor 24 hours.
The n-butanol is evaporated ~d2r vacuum. The residue is taken up in a mixture of 300 ml of acetic acid and 30 ml of concentrated hydrochloric acid. The mixture is heated at 100C for 3 hours. The solution is poured into cold water and the product is left to crystallize.
The solid is filtered off ancl dried.
I,~eight: 44 g M.p.: 160C.
, .: : . - - . .
- : .
2~3~3~
Yield : 69~
3. 6-chloro-3-pllenyl-4-propyl-pyridazine.
250 ml of phosph~s oxychloride are added to 44 g of pyridazinone obtained above and the mi~ture is heated at 80~C for ~
hours. After being left to stan~ o~erni~ht at room temperature, the reaction mixture is concentrated to 3/4 and then poured slowly onto ice. Tl-e mixture is extracted twice with 300 ml of dichloro!nethane, the e~tracts are tlried over sodiwn sul~ate and concentrated.
Chrolna~ography on silica is then carried out by elutin~ h an ethyl acetate-r,lethylene chloride mixture (50/50 v/v).
After recrystallization ~rom isopropyl ether, 43.7 g of the expected product are obtaine~d.
I.p. : 60C
Yield: 9~%.
~) Preparation of 2-diethylamino-2-methyl-propylaMine.
1. 2-diethylamino-2-methyl-propionitrile.
85.1 g of the cyanohydrin of distilled acetone and 73.1 g of diethylamine are mixed, S5.7 g of magnesium sulfate are added and the mixture is heated under gentle reflux for 20 hours with stirrin~.
The sulfate mass which is formed is filtered off and washed with ether.
The filtrate is concentrated and tllen distilled.
86.S g of the expected product are recovered.
Yieltl : 62%
3.p. = 68-70C at 15 mm of mercury.
2. 2-diethylamino 2-methyl propionamide.
To 95.9 g of the nitrile prel~ared in the preceding step 450 ml of sulfuric acid and 70 ml or water are added with stirring and the mixture is heated on an oil bath at 100-110C for 2 hours. The reaction mixture is poured slowly during one hour into 1.4 1 of a 20%
~0 ammonia solution and 400 ml of water cooled in a Dry Ice/acetone bath. The mixture is extracted 3 times with S00 ml of methylene chloride, the extracts are dried over sodium sulEate and concentrated. -The expected product is obtained by distillation.
I1eight : 102.5 g Yield : 95%
, . .:
: - -: . : ~. :: . :
:' : ~ - :: - : - ~ .:
- 2~3~;~3~
B.p. : 13~-139C at 15 mm of mercury.
3. 2-diethylamino-2-me~hyl-propylamine.
A mixture containil~, 52.4 g~ of the ami(l~ prepared in the preceding step and ~0 ml of tetrahydroftlran are heated at 45-50C.
So ml of the borane-dimethylsulEide complex are added under an atmosphere of nitro~en durino one hour and heating is continued for 3 hours on an oil bath at ~0-~5C.
After being left overnight at room temperature, the mixture is cooled in an ice bath, then 315 ml of 6~ llydrochloric acid are added slowly during 3 hours and the mixture is heated again at 135C for 3 hours. After being left overnight at room temperature, the reaction mixture is cooled whilst 200 ml of 30~O~ sodium hydroxide are added.
The mixture is extracted 3 times with 250 ml of ether, the extracts are dried over sodiu,n sulfate and concentrated.
The expected product is obtained by distillation.
~eight: 23 Yield : 48%
3.p. = 71-73C at 15 mm of mercury.
C) SP~ 46559 A
- t~ mixture oE 2.5 g of the chloro derivative obtained above in step A and 4.6 g oE the ~iamine obtained in step B are heated at 120C overnight. 150 ml of ethyl acetate are added, then the mixture is extracted twice with 50 ml of hydrochloric acid. The mixture is then made alkaline by the addition of 50 ml of 30% sodium hydroxide and then extracted with ethyl acetate. The extracts are washed with dilute salt solution, dried over sodium sulfate and concentrated.
Chromatotgraphy on alumina is carried out by eluting with a methylene chloride-ethyl acetate mixture (70/30, v/v~.
3.2 g of an oil is obtained which crystallizes.
.-I.p. = 75-77C
Yield: 87"
Sesquifumarate 3.1 g of the base obtained in the preceding step are taken up in 50 ml of acetone and 1.6 ~ of fumaric acid in 150 ml of ace~one are added. The mixture is filtered hot. The total volume recovered .
.
- , : ~ ~:
- ~ :
- ~ .
.
2~3~.~33 (175 ml) is concentrated to 130 ml. The product i9 allowed to crystallize, the crystals are filtered off and then ~ashed witll acetone.
.l g of the expec~ed product are obtained.
Overall yield of step C = 74,~
`I.p. = 151~C
rXA;~IPL~ 2 S?~ 46559 .~
Aj 6-chloro-3-?henyl-4-propyl-pyridazine, described in e~ample 1.
B) 2-diethylamino-2-methyl--propylannine.
1. Pre?aration of the compound of formula ~VII a) with ~1 = H.
47.14 g of isobutylene are dissolved in 150 ml oE n-heptane, the mixture is cooled to a temperature bet-~een -10 and -20C and 50 g of nitrosyl chloride are added. The temperature is allowed to rise~+5C) during one and a half hours, then the temperature is brought to between 10C and 20C and the mixture is stirred for one and a half hours. The precipitate formed is filteretl off, washed with heptane and then dried.
;I.p. = 102-104C
m = G4 g 2. Preparation oE the compound of forlnula VIII~ 5 = ~6 = C2~15 21.7 g of the compound prepared in the preceding step are suspellded in 150 ml of a~solute alcohol, 39.17 g of diethylamine are added antl the mixture is heated at 60C for 6 hours. An oil is obtained which solidifies.
m = 19.5 g ~ I.p. ~ 50C
3. 2-diethylamino-2-methyl-propylamine 7.01 g of lithium aluminium hydride are added to 50 ml of an ethereal solution of the compound obtained in the preceding step during l hour. After being stirred for one and a half hours at room temperature, the mixture is refluxed for 4 hours. r~hile the mixture is maintained between 0C and -10C, 7.1 ml of water are added during 1 hour, 7.1 i711 of sodium hydroxide durino 30 minutes and 21.3 ml of water during 3G minutes. After being stirred for 2 hours at room :: , . :
:
20~3~
temperature, the solution is filtered, the precipitate is washed ~ith anhydrous ether, the filtrate is dried over sodium sulfate and the solvents are removed un~ervacuum. The pro~uct is distilled:
~.p. = 72-75C at 15 mrn of mercury.
m = 4.2 ~
C) SR 46559 A is then prepared as described in example 1.
EX~`IPLE 3 3-(2-diethylamino-2-methyl-propyl)amino-6-(2-chloro-phenyl)-5-propyl-pyridazine sesquifumarate. SR 47863 A.
1.7 g of 3-chloro 6-(2-chloro-pilenyl) 5-propyl pyridazine and 6 ml of 2-diethylalDino 2-methyl propylamine are heated at 110C
under nitro~en for 20 hours.
After evaporation unde~ vacuum, the mixture is talcen up in dichloromethane and uashed with a solution of sodium bicarbonate. The organic phase is decanted, dried over magnesium sulfate, filtered and concentrated undsrvacuum. The residue is chromatographed on silica nel, eluant: dichloromethane/methanol 98/2.
The conccntration of the pure fractions gives an oil ~hich is dissolved in 10 ml of methanol. Fumaric acid is added, the methanol is evaporated under vacuum and the sesquifumarate crystallizes from ether.
m = l.G ~
~I.p. = 144~C.
E~ lPL~ 4 3-(2-diethylamino-2-methyl-propyl)amino-6-(2-methoxy-phenyl)-5-methyl-pyridazine.
1.6 g of 3-chloro-o-~2-methoxy-phenyl)-5-methyl pyrida~ine, 4 g of 2-diethylamino-2-methyl-propylamine and 0.36 o of ammonium chloride are melted together at 120C and the reaction mixture is left at this temperature for 24 hours.
The mixture is cooled to room temperature, extracted with ethyl acetate and washed with a saturated aqueous solution of sodium chloride.
.
.
,- ., :
12 2~3~3 The orgaIlic phase is separated, ~ried over ~gS0~. filtered and evaporated to Iryness in a vacuum.
The residue is chromatol7rapIled on alumina, eluent: ethyl acetate +2~o of triethylamine.
The concentration of the pure fractions g~ives the e~pected product. Tlle structure is confirZ~Ied by ~iR spectral analysis.
E~A`PL~ 5 3-(2-diethylamino-2-methyl-propyl)amino-5-methyl-6-(2-hydroxy-phenyl)-pyridazine. SR 96376.
1 g oE the product obtained previously in e~ample 4 is dissolved in 50 ml of 4~O hydrobromic acid and the mixture is heated at reflu~ for 4~ hours. After this time, the Ieac-~.on mixture is evaporated to dryness under vacuum, the residue is made allcaline with an aqueous solution of potassium carbonate and the solution is extracted with dicIlloromethane. The org7anic phase is decanted, dried over-i~IOS04.
filtered and evaporated to dryness ~der vacuum.
The residue is chromatographed on alumina, eluent: ethyl acetate/methanol 9/1 + 2% of triethylamine.
The concentration of the pure fractions ~ives a residue which is crystallized from isopropanol.
m = 200 mg ~ 59.2C
~'~A`IPLES 6 T0 35 A) By using the procedure indicated in e~ample lA, but by varying the starting ketone, the 6-chloro-pyridazines assembled in the tables 1 and 2 are obtained.
.: . .~ .
.- , . :
2 ~
OS ~ >\ ~ Cl ___________________________________________________ , : R1 : R2 : R3 : Physical : : constan~s H H -CH2CH2CH3 M.p.: 52-53C
Cl (4) H . -CH3 M.p; 178-180C ;
lS Cl (4) H -CH2CHzCH3 ;M.p; 95C
OCH3 (4) }I ; -CH2CH2C1l3 M.p~ 68-!69C
: H : I{ : CH3 :M.p: 123-124C :
: H H phenyl M.p:. 115C
H H : cyclopropyl M,p.119C
: F (4): H isopropyl :M.p-.89-90C
-. :
: Gl (2) : H : CH2CH2CH3 : oil, NMR ~ :
:
: OCH3(2) : H : CH3 NMR
: : : : :
: H : H : benzy~ :M.p; 92C
:
- 20~13~
Cl (4~ H ; C1-4 phenyl M p... 118-119C
: H : H : Cl-4 phenyl :M.p_ 130C
:
OS : Cl (4) : H : phenyl :M.p; 125C
Cl ~2) Cl (4) CH2CH2CH3 M.p; 71-72C
: Cl (3) : H : CH2cl~2cl~3 :M.p; 48C
: CH3 (4) : H : Cl-4 phenyl :M.p'. 140C
:
: OCI13(2) : ll : C1l2CII2CH3 :oil~ NMR
: OCH3(3) : H : Cll2CH2CH3 :oil, NMR
:
: F ~4) : H : Cl-4 phenyl :M.p. 139C
____ _ ____________________________________________ NMR : NM~ spectral analysis enables the structure of ~he above compounds to be confirmed.
.:
203~33 Ar_\ ~ Cl N-N
: : : Physical Ar : R3 : constants : 2-thienyl : phenyl :M.p: 148C
: 2-C1 5-thienyl . phenyl . NMR
3-pyridyl : phenyl :M.F. 184C
: 2-pyridyl : phenyl : M.p. 138C
: 4-pyridyl : phényl : M.p 193~C
--------------------------------------~~~~~~~~~~~
B) Starting ~rom the chloro derivatives of table 1 and by followinn ~he procedure e~nployed in evample 1, the co~pounds according to the invention assembled in table 3 belo~ are obtained by ~tarying the amines `.lll2~4 use(!.
~ :
, ~ - :
., -:, ~3~3~
3-(2-cliethylamino-2-methyl-propyl)amino-5,6-diphenyl-pyridazine and its salts.
The salts of the compounds of formula I accorcling to the present inventiotl includes those with both mineral and organic acids which enable the compounds of formula I to be separated or suitably crystallized, such as picric acid or oxalic acid, those which form pharmaceutically acceptable salts such as the hydrochloride, hydrobromide, sulfate, hydrogen sulfate, dihydrogen phosphate, methane sulfonate, methyl sulfate, maleate, fumarate, 2-napht~alene sulfonate.
In accordance with a second feature, the present invention relates to a process for the preparation of the compounds of formula (I).
.~ccording to the present invention, the process for the preparation of the compounds of Eormula (I) is characterized in that an amine ~4N7~2 is reacted with a 6-chloro pyridazine of formula:
: ' :
203~33 Ar--<~Cl (II) N_N
in which Ar and R3 have the meanin2s indicated above Eor (I) and, optionally, the compound thus obtained is converted into a salt with a mineral or orOanic acid.
The substitution reaction of the 6-chloro pyrida2ine (II) by the amille R4~H2 is carried out between 100 and 150C, optionally in the presence of ammonium chloride. The reaction is performed without solvent or in the presence of an inert solvent such as n-butanol. ~le product (I) is isolated by extraction and purified, for example, by chromato~raphy.
The product oE formula I thus obtained is isolated in the form of the free base or a salt according to standard techniques.
'lhen the compound of formula I is obtained in the Eorm of the free base, salt formation is carried out by treatment with the selected acid in an organic solvent. By treatment of the free base, dissolved for example in an alcohol such as isopropanol, with a solution oE the selected acid in the same solvent, the correspondin~ salt is obtained which is isolated according to standard techniques. In this way, the hydrochloride, the hydrobromide, the sulfate, the hydrogen sulfate, the dihydrogen phosphate, the methane sulfonate, the methyl sulfate, the oxalate, the maleate, the Eumarate and the 2-naphthalene sulfonate are prepared.
At the end o-E the reaction, the compound of formula I may be isolated in the form of one of its salts, for example the hydrochloride; in this case, if necessary, the free base may be prepared by neutraliæation of the said salt with a mineral or organic base such as sodium hydroxide or triethylamine or an alkali metal carbonate or bicarbonate such as sodium or potassium carbonate or bicarbonate.
~lhen Rl andjor R2 represent a hydroxyl group, the compound according to the invention is obtained startino from compound ~I) in which Rl and/or R2 denote alkoxy and all of the other substituents :
, . . , ~ - - -- . - - : :: ~
~ : ' i - : ~: :
203~3~
have the above definitions, I)y deallcylation using 1cno~/n methods.
The 6-chloro pyridazines (II), used as startino materials, are prepared from the correspon(ling 211-pyrldazin-3-ones (III) by reaction ~ith an e~cess of hot phosphorus oxychloride in the absence oE a solvent or in the presence of an inert solvent such as acetonitrile, accordino to the :Eollot~ing reaction scheme:
Ar ~\ ~ O POCl3 ~II) N-N -->
H
(III) 15The 2EI-pyridazin-3-ones ~III) are known or prepared by known methods.
Tl1us, when P~3 is a Ar' radical, the 211-pyridazin-3-ones are obtainetl according to the method described by P.SCf{MIDT et al. in llelv .
Chim. Acta, l954, 15, 134-140, starting Erom malonic acid tliethyl ester 20antl a hydrazone derivative according to the follo~ino reaction scheme:
Ar'-CO-C-Ar + CH2-CO2C2H5 25Ar~ C02C2Hs Ar~ COOH
- > Ar ~ O - > Ar ~ O
N-N N-H H
Ar' :
- > Ar ~ ~ O :
-N :
1 ~: :
(III) ~ -. .- . ~
2~3~3~
11hen ~3 represents an alkyl or cycloallcyl radical, the compoun(1s ~III) are prepared ~rom a ketone Ar-CO-C~2R3 (1):
CllO R3 OH
COOC2Hs CH-CH
5 Ar-C-C112-R3 -> Ar - C C = O
l 1~sC20 2 lO NH2NH2 CH-CH\ C=C
-----> Ar - C C = O > Ar - C\\ C = O ~
N - N N - ~ -3 ~ (III) H
The hydro~y keto ester 2 is obtained from the ketone 1 by heating it with ethyl ~lyoxylate at a temperature between 80 and 140C.
The crude reaction mixture is then taken up in an inert solvent such as n-butanol and hydrazine hydrate is added. By heating at refluc for 24 hours, the 4,5-dihydro 4-hydro~y pyridazin-3-one 3 is obtained which, when heated in an acidic medium, leads by dehydration to the 211-pyridazin-3-one (III).
The amines R4N112 are known or prepared by lcnown methods.
Thus, when n = O, they rnay be prepared from a cyano derivative of formula:
XlCHz OH
C (IV) XlCH2 CN
By reaction with an amine H~R5R6 by heating at a temperature between 40 and 80C, optionally in the presence of a salt of a strong acid such as sodium sulfate or magnesium sulfate, a compound of formula:
X lCH2 NR5R6 C ~V) XlCH2 CN
:
--. :
, . . - ~ . . ~ .
2~3~3~
is first prepared, then this compound is hydrated by reaction with a strong acid such as hot sulEuric acid in order to produce the corresponding aMide:
XlCH2 / NR5R6 C \ (VI) XlCH2 CONH2 Finally, reduction by heating with a metal hydride such as boron hydride or lithium aluminium hydride leads to the formation of the amine R4Nll2.
~ lhen n = O, the amine P~4N!12 may also be prepared from a chloronitroso derivative (VII) accordino to the procedure described in J. Prakt. Chem., 1978, 320 (3), 433-451.
Xl,CH2 XlCH2 C1 - C - CH2NO + R5R6NH2 - ~ R6RsN - C - CH = NOH
XlCH2 XlCH2 : `
(VII) (VIII) Li Al H4 XlCH2 > R6R5N - C - CH2 - NH2 X lCH2 The compound of formula (VII) may be used in the form o:E
a dimer (VIIa) which is obtained by reaction of nitrosyl chloride with the appropriate olefin (IX) according to the procedure described in J. Prakt. ChemO, 1965, 29 (4), 123.
,C,112 C1~l2Xl ~ O C~2~1 C + NOCl > Cl - C - CH2 - N = N - CH2 - C - Cl X lCH2 CH2X 1 CH2X 1 C112X 1 (IX) (VII a ) ~: . . . -2~3~33 Finally, when n = 1, the amine R4NH2 may be prepared according to the mcthod described in ~eilstein 4 (3)I 5~6, i.e. by reaction o lithiuln aluminium hydride on the oxime (X):
CII2X1 LiAlH4 CI12Xl IIo - N = CH - C - C~Iz - NR5a6 > H2N - CH2 - C - CH2- NRsR6 (X) ine ~II2 ~ CX2C(CI3)2 ~ CH2-~(C~I3)2 is commercially available.
The following exaIllples illustrate the invention without in any way limiting it. The compounds are characterized by their melting point (~I.p.) expressed in degrees centigrade.
E~A,IPLE 1 3-(2-diethylamino-2-methyl-propyl)amino-6-phenyl-5-propyl-pyridazine sesquifumarate: SR 46559 ,~.
A~ 6-chloro-3-phenyL-4-propyl-pyridazine.
1. Ethyl 2-hydroxy-4-oxo-4-phenyl-3-propyl-butyrate.
A mixture of 48.c,7 g of valerophenone and 45.94 g of ethyl ~lyoxylate is heated at 120C Eor 15 hours.
The crucle reaction product is used as such in the following step, 2. 6-phenyl-5-propyl-2rl-pyridazin-3-one.
The crude product obtained above is dissolved in 450 ml of n-butanol, then 30 g of hydrazine hydrate are added and the mixture is heated at reflux -Eor 24 hours.
The n-butanol is evaporated ~d2r vacuum. The residue is taken up in a mixture of 300 ml of acetic acid and 30 ml of concentrated hydrochloric acid. The mixture is heated at 100C for 3 hours. The solution is poured into cold water and the product is left to crystallize.
The solid is filtered off ancl dried.
I,~eight: 44 g M.p.: 160C.
, .: : . - - . .
- : .
2~3~3~
Yield : 69~
3. 6-chloro-3-pllenyl-4-propyl-pyridazine.
250 ml of phosph~s oxychloride are added to 44 g of pyridazinone obtained above and the mi~ture is heated at 80~C for ~
hours. After being left to stan~ o~erni~ht at room temperature, the reaction mixture is concentrated to 3/4 and then poured slowly onto ice. Tl-e mixture is extracted twice with 300 ml of dichloro!nethane, the e~tracts are tlried over sodiwn sul~ate and concentrated.
Chrolna~ography on silica is then carried out by elutin~ h an ethyl acetate-r,lethylene chloride mixture (50/50 v/v).
After recrystallization ~rom isopropyl ether, 43.7 g of the expected product are obtaine~d.
I.p. : 60C
Yield: 9~%.
~) Preparation of 2-diethylamino-2-methyl-propylaMine.
1. 2-diethylamino-2-methyl-propionitrile.
85.1 g of the cyanohydrin of distilled acetone and 73.1 g of diethylamine are mixed, S5.7 g of magnesium sulfate are added and the mixture is heated under gentle reflux for 20 hours with stirrin~.
The sulfate mass which is formed is filtered off and washed with ether.
The filtrate is concentrated and tllen distilled.
86.S g of the expected product are recovered.
Yieltl : 62%
3.p. = 68-70C at 15 mm of mercury.
2. 2-diethylamino 2-methyl propionamide.
To 95.9 g of the nitrile prel~ared in the preceding step 450 ml of sulfuric acid and 70 ml or water are added with stirring and the mixture is heated on an oil bath at 100-110C for 2 hours. The reaction mixture is poured slowly during one hour into 1.4 1 of a 20%
~0 ammonia solution and 400 ml of water cooled in a Dry Ice/acetone bath. The mixture is extracted 3 times with S00 ml of methylene chloride, the extracts are dried over sodium sulEate and concentrated. -The expected product is obtained by distillation.
I1eight : 102.5 g Yield : 95%
, . .:
: - -: . : ~. :: . :
:' : ~ - :: - : - ~ .:
- 2~3~;~3~
B.p. : 13~-139C at 15 mm of mercury.
3. 2-diethylamino-2-me~hyl-propylamine.
A mixture containil~, 52.4 g~ of the ami(l~ prepared in the preceding step and ~0 ml of tetrahydroftlran are heated at 45-50C.
So ml of the borane-dimethylsulEide complex are added under an atmosphere of nitro~en durino one hour and heating is continued for 3 hours on an oil bath at ~0-~5C.
After being left overnight at room temperature, the mixture is cooled in an ice bath, then 315 ml of 6~ llydrochloric acid are added slowly during 3 hours and the mixture is heated again at 135C for 3 hours. After being left overnight at room temperature, the reaction mixture is cooled whilst 200 ml of 30~O~ sodium hydroxide are added.
The mixture is extracted 3 times with 250 ml of ether, the extracts are dried over sodiu,n sulfate and concentrated.
The expected product is obtained by distillation.
~eight: 23 Yield : 48%
3.p. = 71-73C at 15 mm of mercury.
C) SP~ 46559 A
- t~ mixture oE 2.5 g of the chloro derivative obtained above in step A and 4.6 g oE the ~iamine obtained in step B are heated at 120C overnight. 150 ml of ethyl acetate are added, then the mixture is extracted twice with 50 ml of hydrochloric acid. The mixture is then made alkaline by the addition of 50 ml of 30% sodium hydroxide and then extracted with ethyl acetate. The extracts are washed with dilute salt solution, dried over sodium sulfate and concentrated.
Chromatotgraphy on alumina is carried out by eluting with a methylene chloride-ethyl acetate mixture (70/30, v/v~.
3.2 g of an oil is obtained which crystallizes.
.-I.p. = 75-77C
Yield: 87"
Sesquifumarate 3.1 g of the base obtained in the preceding step are taken up in 50 ml of acetone and 1.6 ~ of fumaric acid in 150 ml of ace~one are added. The mixture is filtered hot. The total volume recovered .
.
- , : ~ ~:
- ~ :
- ~ .
.
2~3~.~33 (175 ml) is concentrated to 130 ml. The product i9 allowed to crystallize, the crystals are filtered off and then ~ashed witll acetone.
.l g of the expec~ed product are obtained.
Overall yield of step C = 74,~
`I.p. = 151~C
rXA;~IPL~ 2 S?~ 46559 .~
Aj 6-chloro-3-?henyl-4-propyl-pyridazine, described in e~ample 1.
B) 2-diethylamino-2-methyl--propylannine.
1. Pre?aration of the compound of formula ~VII a) with ~1 = H.
47.14 g of isobutylene are dissolved in 150 ml oE n-heptane, the mixture is cooled to a temperature bet-~een -10 and -20C and 50 g of nitrosyl chloride are added. The temperature is allowed to rise~+5C) during one and a half hours, then the temperature is brought to between 10C and 20C and the mixture is stirred for one and a half hours. The precipitate formed is filteretl off, washed with heptane and then dried.
;I.p. = 102-104C
m = G4 g 2. Preparation oE the compound of forlnula VIII~ 5 = ~6 = C2~15 21.7 g of the compound prepared in the preceding step are suspellded in 150 ml of a~solute alcohol, 39.17 g of diethylamine are added antl the mixture is heated at 60C for 6 hours. An oil is obtained which solidifies.
m = 19.5 g ~ I.p. ~ 50C
3. 2-diethylamino-2-methyl-propylamine 7.01 g of lithium aluminium hydride are added to 50 ml of an ethereal solution of the compound obtained in the preceding step during l hour. After being stirred for one and a half hours at room temperature, the mixture is refluxed for 4 hours. r~hile the mixture is maintained between 0C and -10C, 7.1 ml of water are added during 1 hour, 7.1 i711 of sodium hydroxide durino 30 minutes and 21.3 ml of water during 3G minutes. After being stirred for 2 hours at room :: , . :
:
20~3~
temperature, the solution is filtered, the precipitate is washed ~ith anhydrous ether, the filtrate is dried over sodium sulfate and the solvents are removed un~ervacuum. The pro~uct is distilled:
~.p. = 72-75C at 15 mrn of mercury.
m = 4.2 ~
C) SR 46559 A is then prepared as described in example 1.
EX~`IPLE 3 3-(2-diethylamino-2-methyl-propyl)amino-6-(2-chloro-phenyl)-5-propyl-pyridazine sesquifumarate. SR 47863 A.
1.7 g of 3-chloro 6-(2-chloro-pilenyl) 5-propyl pyridazine and 6 ml of 2-diethylalDino 2-methyl propylamine are heated at 110C
under nitro~en for 20 hours.
After evaporation unde~ vacuum, the mixture is talcen up in dichloromethane and uashed with a solution of sodium bicarbonate. The organic phase is decanted, dried over magnesium sulfate, filtered and concentrated undsrvacuum. The residue is chromatographed on silica nel, eluant: dichloromethane/methanol 98/2.
The conccntration of the pure fractions gives an oil ~hich is dissolved in 10 ml of methanol. Fumaric acid is added, the methanol is evaporated under vacuum and the sesquifumarate crystallizes from ether.
m = l.G ~
~I.p. = 144~C.
E~ lPL~ 4 3-(2-diethylamino-2-methyl-propyl)amino-6-(2-methoxy-phenyl)-5-methyl-pyridazine.
1.6 g of 3-chloro-o-~2-methoxy-phenyl)-5-methyl pyrida~ine, 4 g of 2-diethylamino-2-methyl-propylamine and 0.36 o of ammonium chloride are melted together at 120C and the reaction mixture is left at this temperature for 24 hours.
The mixture is cooled to room temperature, extracted with ethyl acetate and washed with a saturated aqueous solution of sodium chloride.
.
.
,- ., :
12 2~3~3 The orgaIlic phase is separated, ~ried over ~gS0~. filtered and evaporated to Iryness in a vacuum.
The residue is chromatol7rapIled on alumina, eluent: ethyl acetate +2~o of triethylamine.
The concentration of the pure fractions g~ives the e~pected product. Tlle structure is confirZ~Ied by ~iR spectral analysis.
E~A`PL~ 5 3-(2-diethylamino-2-methyl-propyl)amino-5-methyl-6-(2-hydroxy-phenyl)-pyridazine. SR 96376.
1 g oE the product obtained previously in e~ample 4 is dissolved in 50 ml of 4~O hydrobromic acid and the mixture is heated at reflu~ for 4~ hours. After this time, the Ieac-~.on mixture is evaporated to dryness under vacuum, the residue is made allcaline with an aqueous solution of potassium carbonate and the solution is extracted with dicIlloromethane. The org7anic phase is decanted, dried over-i~IOS04.
filtered and evaporated to dryness ~der vacuum.
The residue is chromatographed on alumina, eluent: ethyl acetate/methanol 9/1 + 2% of triethylamine.
The concentration of the pure fractions ~ives a residue which is crystallized from isopropanol.
m = 200 mg ~ 59.2C
~'~A`IPLES 6 T0 35 A) By using the procedure indicated in e~ample lA, but by varying the starting ketone, the 6-chloro-pyridazines assembled in the tables 1 and 2 are obtained.
.: . .~ .
.- , . :
2 ~
OS ~ >\ ~ Cl ___________________________________________________ , : R1 : R2 : R3 : Physical : : constan~s H H -CH2CH2CH3 M.p.: 52-53C
Cl (4) H . -CH3 M.p; 178-180C ;
lS Cl (4) H -CH2CHzCH3 ;M.p; 95C
OCH3 (4) }I ; -CH2CH2C1l3 M.p~ 68-!69C
: H : I{ : CH3 :M.p: 123-124C :
: H H phenyl M.p:. 115C
H H : cyclopropyl M,p.119C
: F (4): H isopropyl :M.p-.89-90C
-. :
: Gl (2) : H : CH2CH2CH3 : oil, NMR ~ :
:
: OCH3(2) : H : CH3 NMR
: : : : :
: H : H : benzy~ :M.p; 92C
:
- 20~13~
Cl (4~ H ; C1-4 phenyl M p... 118-119C
: H : H : Cl-4 phenyl :M.p_ 130C
:
OS : Cl (4) : H : phenyl :M.p; 125C
Cl ~2) Cl (4) CH2CH2CH3 M.p; 71-72C
: Cl (3) : H : CH2cl~2cl~3 :M.p; 48C
: CH3 (4) : H : Cl-4 phenyl :M.p'. 140C
:
: OCI13(2) : ll : C1l2CII2CH3 :oil~ NMR
: OCH3(3) : H : Cll2CH2CH3 :oil, NMR
:
: F ~4) : H : Cl-4 phenyl :M.p. 139C
____ _ ____________________________________________ NMR : NM~ spectral analysis enables the structure of ~he above compounds to be confirmed.
.:
203~33 Ar_\ ~ Cl N-N
: : : Physical Ar : R3 : constants : 2-thienyl : phenyl :M.p: 148C
: 2-C1 5-thienyl . phenyl . NMR
3-pyridyl : phenyl :M.F. 184C
: 2-pyridyl : phenyl : M.p. 138C
: 4-pyridyl : phényl : M.p 193~C
--------------------------------------~~~~~~~~~~~
B) Starting ~rom the chloro derivatives of table 1 and by followinn ~he procedure e~nployed in evample 1, the co~pounds according to the invention assembled in table 3 belo~ are obtained by ~tarying the amines `.lll2~4 use(!.
~ :
, ~ - :
., -:, ~3~3~
4 ~ ~ NH-R4 05 Rl N_N
____________________________________________________________________ :SR No. : sal~ or base:
:Ex. No. : Rl R2 : R3 : R4 : M.p.
: : : : CH3 : di`nydro-I ~ chloride : 46729A : Cl(4) : H : CH3 : CH2C-N > ; - :
: 6 : : : : CH3 ~ : 240-242~ :
: : : : : : sesqui-: 46732A : }I : H : nC3H7 : : fumarate : 7 : : : : : lS9-161C
CH3/C2Hs : Fumarate : 46733A :C1(4) ~ }I : CH3 CH2-C-N\ : 138-140C
: 8 : : : : CH3 C2Hs : 47020A : H : H : CH3 t- ~ : sesquifuma- :
: 9 : : : : : rate 161C
- . . . . . .
: 47047A : H : H : phenyl. " " : fumarate : 10 : : : : : 193C
:- : : : : :
: 47054A : Cl(4) : H : nC3H7 : : sesqui-: 11 : : : : : fumarate :
: : : : : 152-154C
:
: . :. . . :
- , : . . .. : . . ..
, ~ . , , . - . ' - , :
- , : ; . : . -. : , :, 2 ~
: 47068 : oCH3~4): H : nC3H7 : " " : 65-66C base:
: 12 : : : :
:
: 47069A : OH(4) : H : nC3H7 : : hydrobromide:
05 : 13 : : : : : 179-181C
:
: 47097A : H : H : cyclo- : " " : sesqui-: 14 : : : propyl : : fumarate : : : : : : 158-160C
: : : : : : sesqui-: 47098A : F(4) : H : iPr : " " : fumarate : 15 : : : : : hemihydrate :
: : : : : : 143-145C
: : : CH3 ~ : sesqui-: 47138A : H : H : nC3H7 : CII2-C-N O : fumarate : 16 : : : : CH3 ~ : 149-151C
:
: : C1~l3 C~l3 : 164C
: 47153A : H H : phenyl : CH2-c-c~2-~ : sesqui-: 17 : : : : CH3 CH3 : fumarate :
: : : : : CH3/C2Hs : fumarate : 47227A : H : H : benzyl : CH2-C-N~ : 163C
: -18 ~H3 C2H5 : 47297A : Cl (4) : H : Cl-4 : : dihydro-: 19 : . : : phenyl : a~l~ide 138C
: : : : : : hydrate :
: 47608A : H - : H : " : : dihydro-:20 : ~id~ 147C
'' . :- . ' . ' .
, .
--.
2~3~3~
: 47609A : Cl (4) : H : phenyl : " " :d~hydlo 21 chl~id~470c .
: 47655A : Cl (2) :Cl-~4): nC3H7 : " " : sesquifuma- :
05 : 22 : : : : : rate : : : : : : 165-166C
:
: : : : : C2Hs CH3 : base : 47673 : H : H : nC3H7 : CH2-C-N. : oil 1023 : : : : C2Hs CH3 : ~MR
:
: : : : : CH3 C2Hs : sesquifuma- :
: 47878A : Cl (3) : H : nC3H7 : CH2-C-N : rate 146C
: 24 : : : : C~13 C2l~s : 47890A : CH3 (4) : H : Cl-4 : " " dihydro-: 25 : : : phenyl : Chloridle O
:
: 47967 : F (4) : H : Cl-4 : : 98C
: 26 : : phenyl : : base : 48079A : OCH3 (Z) ': H : nC3~17 : : sesquifuma- :
: 27 : : .: : : rate 95C
: 48080 : OH (2) : H : nC3H7 : : 15g,5 C
: 28 : : : : : base : 4808lA : OCH3 (3) : H : nC3H7 : ' dihydro-: 29 : : : : chloride : 48082 : OH (3) : H : nC3H7 : : 166~C
30 : : : : base ________________________________________________ ___________________ :
- : . . . . : : :
;, ,. ~ ~
~ ~ 3 ~
.`r;lR spectrurIl of SR 47673 ~D:IS0 d6; 200 `-~Tz) 0.70 (t: 3 11); O.S0 ~t; 6TI); 1~JO (q; 21l); 1.50 (m; 411);
2.30 (s; ~)ll~; 2.40 (m; 2M); 3,40 (m; 211); 6.20 (In; lll); 6.S0 (s;
lH); 7.35 (s; 5M).
~I~IR spectrum of SR 4SOSl ~
(D`IS0 d; 200 lI!lz) 0.3d (t; 3TM~; 1.40 (m; 31.1); 1.5 (s; 61T); 2.56 ~q; 211);
3.40 (b.s. ; 4Tl); 3,30 (s ; 3~1); 4.00 (d ; 21'); 7.02 (In; 3~1); 7.40 lO (t; l1l~; 7.S3 (b.s.; lM).
The following abbreviations are used for the analysis of a ~ s~ectruIn.
s = singlet ; I).s. : broa(l sin;,let; d : doublet; t : triplet;
q : quadruplet; ;n : multiplet.
15 C) Starting from the chloro derivatives of table 2 and by l~ollowing the pro^edure described in e:cample 1, the compounds according- to the invention asseml)led in table 4 belo~ are obtained by varying the amines .'~112R4 used.
,, .
~, :. . , . : ' . ~ . , .
.
'' ~ ' . ' ' . ' ' ..
2~3~:~33 TA~LE 4 Ar ~ NH R4 ~___________________________________________________________________ : SR No. : Ar : R3 : R4 : Salt or ~ase:
: Ex. No. : : : : :
:: : : CH3 C2H5 : dihydro- : -:47674 A : 2-thienyl : phenyl ~ : CH2-C-N \ Chlrilde3C
:31 : : : CH3 C2H5 : : .
47675 A : 5-Cl : phenyl : " " : dihydro-:32 2-thienyl chloride 130C
:: : : : decomposi-: tion : 47802 A : 3-pyridyl : phcnyl : " " : trihydro- :
33 ' ' , chlnride 225C , : 47803 A : 2-pyridyl : ph~nyl : " " trihydro-: 34 : : ~ oride233C
~5 : 47804 A : 4-pyridyl : phenyl : " " : ~rih~d~o-. :
: 3S : chloride : : : : ~ 239 C
____________________________________________________________________ The compounds according to the invention were studied with .~ --respect to their pharmacological properties and in particular with :~
respect to their affinity for the muscarinic cholinergic receptors .
of type ;~1l and ~12-In vitro, the compounds (I) were assayed according to the technique described by '.~1atson J.D. et al. (Life Science.s, 19S2, 31, . .
.
;
2~3~3~
2019-2029) as far as their affinity for the receptors of type ~ll is concerned and according to the technique described by ~lanmmer 1>~. et al. (`-ature, 19S0, 2S3, 90-92) and llulme I~.C. et al. (~`~olecular Pharmacology, 1973~, 14, 737-750! as far as their af Einity for the receptors of the ~'~2 type is concerned.
The compounds accordino to the invention exhibit good affinity for the receptors of type ~1l and a mar~ced specificity for the central receptors o E type `:ll as opposed to receptors of type li2.
As an exainple, the co npound SR 46559 A showed an inhibitin~ -concentration 50 expressed in micromoles of 0.11 and 2.2, respectively, on the ~ll and i l2 receptors .
Similarly, the compound SR~ 47047 A showed inhibitin~
concentrations 50 o 0.04 and 0.9, respectively, on the `11 and ~t2 receptors .
In vivo, the compollnds accordin~ to the invention were assayed for their effect on the rotations induced by intrastriatal pirenzepine in the test tlescribed by r?orms P, et al. (Psychopharinacology, 19S7, 93, 4S9-493) modified in that the adlninistration of the compounds by the oral route toolc place 4 hours before, instea(l o~ 30 minutes before, the injection of pirenzepirle.
At a dose o E 3 m;-g per Icg of body wei-r,ht, the compoullds according to the invention strongly inhibit the number of rotations induced by pirenzepine. Thus, as an exainple, the compound SR 4G559 A
inhibits the rotations induced by pirenzepine by 73%.
Furtherlllore, the coalpounds according to the invention were shown to be active in the passive avoidance tests in the rat described by Jarvik ;il.E. et al. in Psychol. :led., 19S7, 21, 221-224 and by l~orms P . et al . in Psychopharmacol ., 19S9, 9S , 2~$-2~33.
Thus, according to the results of these tests, the compounds according to the invention counteract the amnesia induced by scopolamine administered by the intraperitoneal route at 0.5 mg~!cg and the amnesia induced by Ipirenzepine administered intraperitoneally at 75 mg/lcg.
For example, SP~ 46559 A exhibits an oral efficien~ dose 50 of 0.25 mg/kg and 0.027 m~,/lcg, respectively,in each of these tests.
'loreover, some compounds according to the invention were - , ', 2~3~3~ .
studied in se~veral predictive models oE antidepressant activity such as the forced suimming test described by Porsolt et al. (Arch. Intern.
Pharmacodyn., 1977, 229, 327-33S) and the test of antagonism of reserpine-induced ptosis described by Gouret et al. (J. Pharmacol.
(Paris), 1977, o, 333-350). S~ 46559 A in particular was shown to be inactive in these tests at oral doses varyillg from 0.1 to 10 mg/lcg.
linally,the compounds according to the invention did not sho~ any sign of toxicity at the doses at which tlley are active.
Consequently, the compounds ~I) may be used as medicines.
The results indicated show that the compoun(ls according to the invention e~hibit good affinity for the muscarinic receptors and good activity in the tests of amnesia induced by scopolamine or pirenzepine. They allow the use of the products accordillO to the invention to be contemplated in all cases in which a cholinergic deficit is indicated and particularly Eor the treatinent of cognitive and memory disorders, and degenerative syndromes associated with senescence and senile dementia.
In accordance with another of its features, the present application thus relates to pharmaceutical compositions containing at least one of the compoull(ls of formula (I) or one oE their salts as active ingredient.
In the pharmaceutical compositions of the present invention for oral, sublingual, transdermal or rectal administration, the active ingredients of formula I above may be administered in specific forms of administration, in combination with the standard pharmaceutical ~
vehicles, to humans especially for the treatment oE cognitive or memory ;-disorders or degenerative syndromes. ~he appropriate specific forms of administration comprise the forms used for the oral route such as tablets, capsules, powders, granules and solutions or oral suspensions, the forms used for sublingual and buccal administration, the forms for subcutaneous, intramuscular or intravenous administration and the forms for rectal administration.
In order to obtain the desired effect, the dose of the active ingredient may vary between 0.5 and 500 mg per day.
: :
.
, :. ~
2 ~ 3 ~
Each unit dose may contain from 0.1 to 100 mo of active inoredient in combination with a pharmaceutical vehicle. This unit dose may be administered 1 to 5 times per clay.
~Ihen a solid composition is prepared in the form of tablets the principaL active ingredient is mixed with a pharmaceutical vehicle such as gelatine starch lactose magnesium stearate talc num arabic, or si;nilar substances. The tablets may be coated with sucrose or other suitable materials or they may be treatetl so that they have sustained or clelayed activity and so that they release continuously a predetermined amount of active ingredient.
t~ preparation oi- capsules is obtained by nixinO the active ingredient ~ith a diluent and ~y pourino the mixture obtained into soft or hard capsules.
The powders or granules dispe~sible in water may contain the active ingredient mixed with dispersing agents or wetting agents or suspending agents such as polyvinylpyrrolidone as well as with sweeteners or taste modifiers.
In the case of rectal administration suppositories are used which are prepared with binders me~tino at the rectal ten~perature, for example cocoa butter or polyethylene glycols.
~or parenteral administration aclueous suspensiolls, isotonic saline solutions or sterile ancl injectable solutions which contain pharmacologically compatible wetting andfor dispersing agents, for example propylene glycol or butylene glycol are used.
The active ingredient may also be formulated in the form of microcapsules, with or without one or more additives or supports.
As an example of a galenic preparation capsules may oe prepared containing:
SR 46559 l~ 0.010 8 ~0 Lactose 0.050 g .~iagnesium stearate 0.005 g by mixing the aboYe ingredients intima~ely and pouring the mixture into gelules of hard gelatine.
.:
. ~ .
. ' ~.
, .
____________________________________________________________________ :SR No. : sal~ or base:
:Ex. No. : Rl R2 : R3 : R4 : M.p.
: : : : CH3 : di`nydro-I ~ chloride : 46729A : Cl(4) : H : CH3 : CH2C-N > ; - :
: 6 : : : : CH3 ~ : 240-242~ :
: : : : : : sesqui-: 46732A : }I : H : nC3H7 : : fumarate : 7 : : : : : lS9-161C
CH3/C2Hs : Fumarate : 46733A :C1(4) ~ }I : CH3 CH2-C-N\ : 138-140C
: 8 : : : : CH3 C2Hs : 47020A : H : H : CH3 t- ~ : sesquifuma- :
: 9 : : : : : rate 161C
- . . . . . .
: 47047A : H : H : phenyl. " " : fumarate : 10 : : : : : 193C
:- : : : : :
: 47054A : Cl(4) : H : nC3H7 : : sesqui-: 11 : : : : : fumarate :
: : : : : 152-154C
:
: . :. . . :
- , : . . .. : . . ..
, ~ . , , . - . ' - , :
- , : ; . : . -. : , :, 2 ~
: 47068 : oCH3~4): H : nC3H7 : " " : 65-66C base:
: 12 : : : :
:
: 47069A : OH(4) : H : nC3H7 : : hydrobromide:
05 : 13 : : : : : 179-181C
:
: 47097A : H : H : cyclo- : " " : sesqui-: 14 : : : propyl : : fumarate : : : : : : 158-160C
: : : : : : sesqui-: 47098A : F(4) : H : iPr : " " : fumarate : 15 : : : : : hemihydrate :
: : : : : : 143-145C
: : : CH3 ~ : sesqui-: 47138A : H : H : nC3H7 : CII2-C-N O : fumarate : 16 : : : : CH3 ~ : 149-151C
:
: : C1~l3 C~l3 : 164C
: 47153A : H H : phenyl : CH2-c-c~2-~ : sesqui-: 17 : : : : CH3 CH3 : fumarate :
: : : : : CH3/C2Hs : fumarate : 47227A : H : H : benzyl : CH2-C-N~ : 163C
: -18 ~H3 C2H5 : 47297A : Cl (4) : H : Cl-4 : : dihydro-: 19 : . : : phenyl : a~l~ide 138C
: : : : : : hydrate :
: 47608A : H - : H : " : : dihydro-:20 : ~id~ 147C
'' . :- . ' . ' .
, .
--.
2~3~3~
: 47609A : Cl (4) : H : phenyl : " " :d~hydlo 21 chl~id~470c .
: 47655A : Cl (2) :Cl-~4): nC3H7 : " " : sesquifuma- :
05 : 22 : : : : : rate : : : : : : 165-166C
:
: : : : : C2Hs CH3 : base : 47673 : H : H : nC3H7 : CH2-C-N. : oil 1023 : : : : C2Hs CH3 : ~MR
:
: : : : : CH3 C2Hs : sesquifuma- :
: 47878A : Cl (3) : H : nC3H7 : CH2-C-N : rate 146C
: 24 : : : : C~13 C2l~s : 47890A : CH3 (4) : H : Cl-4 : " " dihydro-: 25 : : : phenyl : Chloridle O
:
: 47967 : F (4) : H : Cl-4 : : 98C
: 26 : : phenyl : : base : 48079A : OCH3 (Z) ': H : nC3~17 : : sesquifuma- :
: 27 : : .: : : rate 95C
: 48080 : OH (2) : H : nC3H7 : : 15g,5 C
: 28 : : : : : base : 4808lA : OCH3 (3) : H : nC3H7 : ' dihydro-: 29 : : : : chloride : 48082 : OH (3) : H : nC3H7 : : 166~C
30 : : : : base ________________________________________________ ___________________ :
- : . . . . : : :
;, ,. ~ ~
~ ~ 3 ~
.`r;lR spectrurIl of SR 47673 ~D:IS0 d6; 200 `-~Tz) 0.70 (t: 3 11); O.S0 ~t; 6TI); 1~JO (q; 21l); 1.50 (m; 411);
2.30 (s; ~)ll~; 2.40 (m; 2M); 3,40 (m; 211); 6.20 (In; lll); 6.S0 (s;
lH); 7.35 (s; 5M).
~I~IR spectrum of SR 4SOSl ~
(D`IS0 d; 200 lI!lz) 0.3d (t; 3TM~; 1.40 (m; 31.1); 1.5 (s; 61T); 2.56 ~q; 211);
3.40 (b.s. ; 4Tl); 3,30 (s ; 3~1); 4.00 (d ; 21'); 7.02 (In; 3~1); 7.40 lO (t; l1l~; 7.S3 (b.s.; lM).
The following abbreviations are used for the analysis of a ~ s~ectruIn.
s = singlet ; I).s. : broa(l sin;,let; d : doublet; t : triplet;
q : quadruplet; ;n : multiplet.
15 C) Starting from the chloro derivatives of table 2 and by l~ollowing the pro^edure described in e:cample 1, the compounds according- to the invention asseml)led in table 4 belo~ are obtained by varying the amines .'~112R4 used.
,, .
~, :. . , . : ' . ~ . , .
.
'' ~ ' . ' ' . ' ' ..
2~3~:~33 TA~LE 4 Ar ~ NH R4 ~___________________________________________________________________ : SR No. : Ar : R3 : R4 : Salt or ~ase:
: Ex. No. : : : : :
:: : : CH3 C2H5 : dihydro- : -:47674 A : 2-thienyl : phenyl ~ : CH2-C-N \ Chlrilde3C
:31 : : : CH3 C2H5 : : .
47675 A : 5-Cl : phenyl : " " : dihydro-:32 2-thienyl chloride 130C
:: : : : decomposi-: tion : 47802 A : 3-pyridyl : phcnyl : " " : trihydro- :
33 ' ' , chlnride 225C , : 47803 A : 2-pyridyl : ph~nyl : " " trihydro-: 34 : : ~ oride233C
~5 : 47804 A : 4-pyridyl : phenyl : " " : ~rih~d~o-. :
: 3S : chloride : : : : ~ 239 C
____________________________________________________________________ The compounds according to the invention were studied with .~ --respect to their pharmacological properties and in particular with :~
respect to their affinity for the muscarinic cholinergic receptors .
of type ;~1l and ~12-In vitro, the compounds (I) were assayed according to the technique described by '.~1atson J.D. et al. (Life Science.s, 19S2, 31, . .
.
;
2~3~3~
2019-2029) as far as their affinity for the receptors of type ~ll is concerned and according to the technique described by ~lanmmer 1>~. et al. (`-ature, 19S0, 2S3, 90-92) and llulme I~.C. et al. (~`~olecular Pharmacology, 1973~, 14, 737-750! as far as their af Einity for the receptors of the ~'~2 type is concerned.
The compounds accordino to the invention exhibit good affinity for the receptors of type ~1l and a mar~ced specificity for the central receptors o E type `:ll as opposed to receptors of type li2.
As an exainple, the co npound SR 46559 A showed an inhibitin~ -concentration 50 expressed in micromoles of 0.11 and 2.2, respectively, on the ~ll and i l2 receptors .
Similarly, the compound SR~ 47047 A showed inhibitin~
concentrations 50 o 0.04 and 0.9, respectively, on the `11 and ~t2 receptors .
In vivo, the compollnds accordin~ to the invention were assayed for their effect on the rotations induced by intrastriatal pirenzepine in the test tlescribed by r?orms P, et al. (Psychopharinacology, 19S7, 93, 4S9-493) modified in that the adlninistration of the compounds by the oral route toolc place 4 hours before, instea(l o~ 30 minutes before, the injection of pirenzepirle.
At a dose o E 3 m;-g per Icg of body wei-r,ht, the compoullds according to the invention strongly inhibit the number of rotations induced by pirenzepine. Thus, as an exainple, the compound SR 4G559 A
inhibits the rotations induced by pirenzepine by 73%.
Furtherlllore, the coalpounds according to the invention were shown to be active in the passive avoidance tests in the rat described by Jarvik ;il.E. et al. in Psychol. :led., 19S7, 21, 221-224 and by l~orms P . et al . in Psychopharmacol ., 19S9, 9S , 2~$-2~33.
Thus, according to the results of these tests, the compounds according to the invention counteract the amnesia induced by scopolamine administered by the intraperitoneal route at 0.5 mg~!cg and the amnesia induced by Ipirenzepine administered intraperitoneally at 75 mg/lcg.
For example, SP~ 46559 A exhibits an oral efficien~ dose 50 of 0.25 mg/kg and 0.027 m~,/lcg, respectively,in each of these tests.
'loreover, some compounds according to the invention were - , ', 2~3~3~ .
studied in se~veral predictive models oE antidepressant activity such as the forced suimming test described by Porsolt et al. (Arch. Intern.
Pharmacodyn., 1977, 229, 327-33S) and the test of antagonism of reserpine-induced ptosis described by Gouret et al. (J. Pharmacol.
(Paris), 1977, o, 333-350). S~ 46559 A in particular was shown to be inactive in these tests at oral doses varyillg from 0.1 to 10 mg/lcg.
linally,the compounds according to the invention did not sho~ any sign of toxicity at the doses at which tlley are active.
Consequently, the compounds ~I) may be used as medicines.
The results indicated show that the compoun(ls according to the invention e~hibit good affinity for the muscarinic receptors and good activity in the tests of amnesia induced by scopolamine or pirenzepine. They allow the use of the products accordillO to the invention to be contemplated in all cases in which a cholinergic deficit is indicated and particularly Eor the treatinent of cognitive and memory disorders, and degenerative syndromes associated with senescence and senile dementia.
In accordance with another of its features, the present application thus relates to pharmaceutical compositions containing at least one of the compoull(ls of formula (I) or one oE their salts as active ingredient.
In the pharmaceutical compositions of the present invention for oral, sublingual, transdermal or rectal administration, the active ingredients of formula I above may be administered in specific forms of administration, in combination with the standard pharmaceutical ~
vehicles, to humans especially for the treatment oE cognitive or memory ;-disorders or degenerative syndromes. ~he appropriate specific forms of administration comprise the forms used for the oral route such as tablets, capsules, powders, granules and solutions or oral suspensions, the forms used for sublingual and buccal administration, the forms for subcutaneous, intramuscular or intravenous administration and the forms for rectal administration.
In order to obtain the desired effect, the dose of the active ingredient may vary between 0.5 and 500 mg per day.
: :
.
, :. ~
2 ~ 3 ~
Each unit dose may contain from 0.1 to 100 mo of active inoredient in combination with a pharmaceutical vehicle. This unit dose may be administered 1 to 5 times per clay.
~Ihen a solid composition is prepared in the form of tablets the principaL active ingredient is mixed with a pharmaceutical vehicle such as gelatine starch lactose magnesium stearate talc num arabic, or si;nilar substances. The tablets may be coated with sucrose or other suitable materials or they may be treatetl so that they have sustained or clelayed activity and so that they release continuously a predetermined amount of active ingredient.
t~ preparation oi- capsules is obtained by nixinO the active ingredient ~ith a diluent and ~y pourino the mixture obtained into soft or hard capsules.
The powders or granules dispe~sible in water may contain the active ingredient mixed with dispersing agents or wetting agents or suspending agents such as polyvinylpyrrolidone as well as with sweeteners or taste modifiers.
In the case of rectal administration suppositories are used which are prepared with binders me~tino at the rectal ten~perature, for example cocoa butter or polyethylene glycols.
~or parenteral administration aclueous suspensiolls, isotonic saline solutions or sterile ancl injectable solutions which contain pharmacologically compatible wetting andfor dispersing agents, for example propylene glycol or butylene glycol are used.
The active ingredient may also be formulated in the form of microcapsules, with or without one or more additives or supports.
As an example of a galenic preparation capsules may oe prepared containing:
SR 46559 l~ 0.010 8 ~0 Lactose 0.050 g .~iagnesium stearate 0.005 g by mixing the aboYe ingredients intima~ely and pouring the mixture into gelules of hard gelatine.
.:
. ~ .
. ' ~.
, .
Claims (7)
1. Compound of formula:
(I) in which :
- Ar represents a phenyl group substituted by R1 and R2 or a hetero-cyclic radical such as a pyridyl group, unsubstituted or substituted by methyl or methoxy, or a thienyl group, unsubstituted or substituted by chlorine, methyl or methoxy.
- R1 and R2 each independently denotes hydrogen, halogen, trifluoro-methyl, hydroxyl, C1-C4 alkoxy or C1-C4 alkyl;
- R3 represents linear or branched C1-C4 alkyl, C3-C7 cycloalkyl, benzyl, phenethyl or the Ar' radical, Ar' being phenyl substituted by R1 and R2;
- R4 represents:
a group, with n = O or 1 in which X1 represents hydrogen or methyl;
- R5 represents a C1-C6 linear alkyl group;
- R6 represents a C1-C6 linear alkyl group, or R5 and R6 also constitute with the nitrogen atom to which they are attached a heterocycle selected from morpholine, pyrrolidine or piperidine;
as well as its salts with mineral or organic acids.
(I) in which :
- Ar represents a phenyl group substituted by R1 and R2 or a hetero-cyclic radical such as a pyridyl group, unsubstituted or substituted by methyl or methoxy, or a thienyl group, unsubstituted or substituted by chlorine, methyl or methoxy.
- R1 and R2 each independently denotes hydrogen, halogen, trifluoro-methyl, hydroxyl, C1-C4 alkoxy or C1-C4 alkyl;
- R3 represents linear or branched C1-C4 alkyl, C3-C7 cycloalkyl, benzyl, phenethyl or the Ar' radical, Ar' being phenyl substituted by R1 and R2;
- R4 represents:
a group, with n = O or 1 in which X1 represents hydrogen or methyl;
- R5 represents a C1-C6 linear alkyl group;
- R6 represents a C1-C6 linear alkyl group, or R5 and R6 also constitute with the nitrogen atom to which they are attached a heterocycle selected from morpholine, pyrrolidine or piperidine;
as well as its salts with mineral or organic acids.
2. Compound according to Claim 1 in which:
- Ar represents phenyl, unsubstituted or substituted at position 2 by chlorine, hydroxyl or methoxy;
- R3 represents phenyl or n-propyl;
- R5 and R6 each represents ethyl;
n = O and X1 = II;
as well as its salts with mineral or organic acids.
- Ar represents phenyl, unsubstituted or substituted at position 2 by chlorine, hydroxyl or methoxy;
- R3 represents phenyl or n-propyl;
- R5 and R6 each represents ethyl;
n = O and X1 = II;
as well as its salts with mineral or organic acids.
3. 3-N-(2-diethylamino 2-methyl propyl) 6-phenyl 5-propyl pyridazinamine and its salts.
4. 3-N-(2-diethylamino 2-methyl propyl) 5,6-diphenyl pyridazinamine and its salts.
5. Process for the preparation of a compound according to Claim 1, characterized in that an amine R4NH2 reacts with a 6-chloro pyridazine of formula:
(II) in which Ar and R3 have the same meanings as in Claim 1 and, optionally, the compound thus obtained is converted into a salt with a mineral or organic acid.
(II) in which Ar and R3 have the same meanings as in Claim 1 and, optionally, the compound thus obtained is converted into a salt with a mineral or organic acid.
6. Pharmaceutical composition characterized in that it contains as active ingredient one compound according to any one of the Claims 1 to 4.
7. Pharmaceutical composition according to Claim 6, characterized in that it contains from 0.5 to 100 mg of active ingredient per dosage unit.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR8915137A FR2654727B1 (en) | 1989-11-17 | 1989-11-17 | PYRIDAZINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME. |
FR8915137 | 1989-11-17 | ||
FR9007533 | 1990-06-15 | ||
FR909007533A FR2663326B2 (en) | 1989-11-17 | 1990-06-15 | PYRIDAZINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME. |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2030133C CA2030133C (en) | 1991-05-18 |
CA2030133A1 true CA2030133A1 (en) | 1991-05-18 |
Family
ID=26227673
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002030133A Granted CA2030133A1 (en) | 1989-11-17 | 1990-11-16 | Pyridazine derivatives, process for their preparation and pharmaceutical compositions containing them |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP0429344B1 (en) |
JP (1) | JPH03170465A (en) |
KR (1) | KR0164599B1 (en) |
AR (1) | AR247557A1 (en) |
AT (1) | ATE143010T1 (en) |
AU (1) | AU639043B2 (en) |
CA (1) | CA2030133A1 (en) |
DE (1) | DE69028602T2 (en) |
DK (1) | DK0429344T3 (en) |
ES (1) | ES2094146T3 (en) |
FI (1) | FI101881B1 (en) |
FR (1) | FR2663326B2 (en) |
GR (1) | GR3021933T3 (en) |
HK (1) | HK1000597A1 (en) |
HU (2) | HU207852B (en) |
IE (1) | IE75697B1 (en) |
IL (1) | IL96384A (en) |
LV (1) | LV11972B (en) |
NO (1) | NO178967C (en) |
NZ (1) | NZ236107A (en) |
PT (1) | PT95902B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022166890A1 (en) * | 2021-02-08 | 2022-08-11 | 南京明德新药研发有限公司 | Substituted pyridazine phenol derivatives |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2665442B1 (en) * | 1990-07-31 | 1992-12-04 | Sanofi Sa | ALKYL-6 PYRIDAZINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME. |
FR2676444B1 (en) * | 1991-05-16 | 1995-03-10 | Sanofi Elf | NOVEL AMINO-3 PYRIDAZINE DERIVATIVES ACTIVE IN THE CENTRAL NERVOUS SYSTEM, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME. |
NZ326354A (en) * | 1996-01-15 | 1999-05-28 | Janssen Pharmaceutica Nv | 3-(substituted-1-piperazinyl)-6-(substituted-1,2,4-thiadiazol-5 -yl)-pyridazine derivatives and medicaments |
WO1999032448A1 (en) * | 1997-12-19 | 1999-07-01 | Amgen Inc. | Substituted pyridine and pyridazine compounds and their pharmaceutical use |
US6528529B1 (en) | 1998-03-31 | 2003-03-04 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
WO2002076391A2 (en) | 2001-03-23 | 2002-10-03 | Advanced Bionutrition | Microbial feeds for aquaculture and agriculture |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
EP2275095A3 (en) | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
RU2416609C2 (en) * | 2005-12-07 | 2011-04-20 | Сумитомо Кемикал Компани, Лимитед | Pyridazine compound and use thereof |
FR2904314A1 (en) * | 2006-07-26 | 2008-02-01 | Centre Nat Rech Scient | LINEAR PYRIDAZINIC AND PYRROLIC COMPOUNDS, METHODS OF OBTAINING AND APPLICATIONS |
AR081331A1 (en) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | AMINO- PYRIMIDINES COMPOSITIONS OF THE SAME AND METHODS FOR THE USE OF THE SAME |
US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
AR081626A1 (en) * | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | AMINO-PYRIDAZINIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME TO TREAT CARDIAC AND SKELETIC MUSCULAR DISORDERS |
AR119731A1 (en) | 2019-05-17 | 2022-01-05 | Novartis Ag | NLRP3 INFLAMASOME INHIBITORS |
CN115279739B (en) * | 2020-03-27 | 2025-07-22 | 尼科治疗有限公司 | Substituted pyridazine compounds |
TW202406550A (en) | 2022-08-03 | 2024-02-16 | 瑞士商諾華公司 | Nlrp3 inflammasome inhibitors |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2510998B1 (en) * | 1981-08-07 | 1986-01-10 | Sanofi Sa | NOVEL AMINO DERIVATIVES OF PYRIDAZINE, PROCESS FOR THEIR PREPARATION AND DRINKING ACTS THEREOF |
FR2540113A1 (en) * | 1983-01-27 | 1984-08-03 | Sanofi Sa | PYRIDAZINE DERIVATIVE ACIDS ACTIVE ON THE CENTRAL NERVOUS SYSTEM |
DE3629929A1 (en) * | 1986-09-03 | 1988-03-10 | Thomae Gmbh Dr K | NEW SULFONAMIDO-AETHYL COMPOUNDS, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF |
FR2642648B1 (en) * | 1989-02-07 | 1991-06-21 | Sanofi Sa | USE OF ALKYL-5 PYRIDAZINE DERIVATIVES AS ACTIVE MEDICAMENTS ON THE CHOLINERGIC SYSTEM |
PT93060B (en) * | 1989-02-07 | 1995-12-29 | Sanofi Sa | METHOD FOR OBTAINING PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
-
1990
- 1990-06-15 FR FR909007533A patent/FR2663326B2/en not_active Expired - Lifetime
- 1990-11-15 PT PT95902A patent/PT95902B/en not_active IP Right Cessation
- 1990-11-15 FI FI905663A patent/FI101881B1/en not_active IP Right Cessation
- 1990-11-16 EP EP90403239A patent/EP0429344B1/en not_active Expired - Lifetime
- 1990-11-16 HU HU907178A patent/HU207852B/en not_active IP Right Cessation
- 1990-11-16 AT AT90403239T patent/ATE143010T1/en not_active IP Right Cessation
- 1990-11-16 DE DE69028602T patent/DE69028602T2/en not_active Expired - Fee Related
- 1990-11-16 ES ES90403239T patent/ES2094146T3/en not_active Expired - Lifetime
- 1990-11-16 CA CA002030133A patent/CA2030133A1/en active Granted
- 1990-11-16 JP JP2312597A patent/JPH03170465A/en active Pending
- 1990-11-16 NZ NZ236107A patent/NZ236107A/en unknown
- 1990-11-16 AR AR90318401A patent/AR247557A1/en active
- 1990-11-16 AU AU66672/90A patent/AU639043B2/en not_active Ceased
- 1990-11-16 NO NO904984A patent/NO178967C/en unknown
- 1990-11-16 DK DK90403239.8T patent/DK0429344T3/da active
- 1990-11-16 IE IE414590A patent/IE75697B1/en not_active IP Right Cessation
- 1990-11-17 KR KR1019900018663A patent/KR0164599B1/en not_active Expired - Fee Related
- 1990-11-18 IL IL9638490A patent/IL96384A/en not_active IP Right Cessation
-
1995
- 1995-06-27 HU HU95P/P00450P patent/HU211351A9/en unknown
-
1996
- 1996-12-06 GR GR960403344T patent/GR3021933T3/en unknown
-
1997
- 1997-09-10 LV LVP-97-165A patent/LV11972B/en unknown
- 1997-11-10 HK HK97102147A patent/HK1000597A1/en not_active IP Right Cessation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022166890A1 (en) * | 2021-02-08 | 2022-08-11 | 南京明德新药研发有限公司 | Substituted pyridazine phenol derivatives |
CN116867769A (en) * | 2021-02-08 | 2023-10-10 | 南京明德新药研发有限公司 | Substituted pyridazine phenol derivatives |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2030133A1 (en) | Pyridazine derivatives, process for their preparation and pharmaceutical compositions containing them | |
EP0482208B1 (en) | Pyridazinone derivative | |
AU725652B2 (en) | Arylalkanoylpyridazines | |
US4612376A (en) | Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent | |
NO309679B1 (en) | Arylalkyldiazinones, pharmaceutical preparations and use of the compounds for the manufacture of drugs | |
SK282708B6 (en) | D4 receptor selectivity piperazine derivatives their preparation method, use and pharmaceutical preparation containing them | |
HK1000597B (en) | Pyridazine derivatives, process for their preparation and pharmaceutical compositions containing them | |
CA1246564A (en) | 1-(AMINOALKYL) -.alpha., .alpha.-DIARYL PYRROLIDINE-, PIPERIDINE- AND HOMOPIPERIDINE- ACETAMIDES AND ACETONITRILES | |
SK279472B6 (en) | PHENOXY AND PHENOXYALKYLPIPERIDINS, PHARMACEUTICAL PRO | |
IE921557A1 (en) | Novel 3-aminopyridazine derivatives active on the central nervous system, method of preparation and pharmaceutical compositions in which they are present | |
JPH0641455B2 (en) | Pyridazinone derivative | |
US5852019A (en) | Pyrimidinylpyrazole derivatives | |
CA2009501A1 (en) | Pyradazine derivatives, method of preparation and pharmaceutical compositions in which they are present | |
CA1271751A (en) | Dihydroimidazo[1,2-a]pyrimidine derivatives | |
CA1144165A (en) | N-pyrrolyl pyridazineamines | |
KR100255416B1 (en) | Pyridazinone derivatives with pharmaceutical activity | |
US5656631A (en) | Pyridazine derivatives | |
US5081119A (en) | Use of 5-alkylpyridazine derivatives as drugs active on the cholinergic system | |
AU752967B2 (en) | Process for the preparation of a 3(2H)-pyridazinone- 4-substituted amino- 5-chloro- derivative | |
CA2048162A1 (en) | 6-alkylpyridazine derivatives, method of preparation and pharmaceutical compositions in which they are present | |
US5077295A (en) | Antipsychoic 4-(4-(3-benzisothiazolyl)-1-piperazinyl)buytl bridged bicycle imides | |
HK1001396B (en) | Pyrimidinylpyrazole derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |